Do Analysts Agree Friday on Day One Biopharmaceuticals Inc (DAWN) Stock's Target Price?

Friday, January 21, 2022 02:22 PM | InvestorsObserver Analysts

Mentioned in this article

InvestorsObserver is giving Day One Biopharmaceuticals Inc (DAWN) an Analyst Rating Rank of 74, meaning DAWN is ranked higher by analysts than 74% of stocks. The average price target for DAWN is $35 and analyst’s rate the stock as a Strong Buy.

Wall Street analysts are rating DAWN a Strong Buy today. Find out what this means to you and get the rest of the rankings on DAWN!
See Full DAWN Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Day One Biopharmaceuticals Inc Stock Today?

Day One Biopharmaceuticals Inc (DAWN) stock is trading at $14.77 as of 2:19 PM on Friday, Jan 21, a decline of -$0.01, or -0.07% from the previous closing price of $14.78. Volume today is 276,522 compared to average volume of 320,505. The stock has traded between $14.61 and $15.61 so far today. Click Here to get the full Stock Report for Day One Biopharmaceuticals Inc stock.

Share this article:

Related Articles